| Miguel Martín, Hospital General Universitario Gregorio Marañón, Madrid, Spain |
| Chair: Ángel Guerrero, Instituto Valenciano de Oncología (IVO), Valencia, Spain |
|
| 16:45 - 17:05 | In vivo models in breast cancer research: where are we now Karen Blyth, Beatson Institute for Cancer Research, Glasgow, UK |
| 17:05 - 17:25 | Overcoming endocrine resistance in breast cancer Ángel Guerrero, Instituto Valenciano de Oncología (IVO), Valencia, Spain |
| 17:25 - 17:45 | Proton-therapy of Cancer: advantages over standard radiation and current indications Felipe Calvo, Clínica Universidad de Navarra, Madrid, Spain |
| 17:45 - 18:15 | Discussion |
| Chair: Luis Costa, Hospital de Santa Maria, Lisbon, Portugal |
|
| 18:30 - 18:50 | PARP-1 inhibitors: Any role as neoadjuvant therapy of early BRCA-1/2 associated breast cancer? Steven Isakoff, Massachusetts General Hospital Cancer Center, Boston, USA |
| 18:50 - 19:10 | Advances in the adjuvant treatment of HR+/HER2- early breast cancer Miguel Martín, Hospital General Universitario Gregorio Marañón, Madrid, Spain |
| 19:10 - 19:30 | Chemo-immunotherapy for early triple negative breast cancer: which drugs? Priyanka Sharma, University of Kansas Medical Center, Kansas City, USA |
| 19:30 - 20:00 | Discussion |